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hip arthroplasty. Cells were cultured in DMEM with 10% FCS con- 
taining CS (1-100 i~g/ml) with medium change every 2 days. Af- 
ter 4 days, culture medium was replaced with serum free DMEM 
containing 1% ITS with or without IL-11~ (1 ng/ml) and then, the 
incubation was further continued for 24 or 48 h. At the end of ex- 
periments, culture medium was harvested for HA assay, using an 
ELISA-like method. RNA was isolated and reverse transcribed to 
cDNA, which was then subjected to the relative quantitative real- 
time PCR (Q-RT-PCR) procedure, using the ABI PRISM 7000 
and SYBR green detection and specific primers for hyaluronan 
synthases (HAS) 1, 2 and 3 and UDP-glucose dehydrogenase 
(UGDH). RT-PCR data were normalized with GAPDH mRNA and 
gene expression relative to control was calculated with the delta 
delta cycle to threshold (ddCt) method. 
Results: IL-11~ was found to dramatically increase HA produc- 
tion by synoviocytes and articular chondrocytes. CS stimulated 
HA production by these cells, in a dose and time dependent 
manner. The effect of CS was observed for both basal and IL- 
l I~ induced HA levels. The cytokine increased mRNA expression 
of HAS1 and HAS2 in the two cell types, with greater effect on 
HAS1 than HAS2 whereas CS induced equivalent stimulation on 
both genes. As for HA production, the effect of CS on HAS1 and 
HAS2 expression was observed for basal and IL-11~ induced ex- 
pression. UGDH expression was stimulated by IL-11~ in chondro- 
cytes only. CS stimulated basal and IL-11~ induced mRNA expres- 
sion of UGDH in both synoviocytes and chondrocytes. Expres- 
sion of HAS3, rather implicated in synthesis of low molecular HA 
species, was found to be stimulated by IL-11~ in the two articular 
cells. Interestingly, CS inhibited HAS3 expression and repressed 
the IL-11~ induced stimulation of this gene in chondrocytes. Work 
is in progress to determine the molecular size of HA produced in 
these experimental conditions. 
Conclusion: CS enhanced HA production by articular cells. The 
effect is associated with concomitant increase of UGDH, HAS1 
and HAS2 mRNA expression. In contrast, the expression of 
HAS3, the enzyme involved in synthesis of low molecular forms 
of HA is depressed by CS. These findings suggest that CS could 
exert its beneficial effect on OA symptoms through increased HA 
release in the synovial fluid and enhanced aggregating potential 
for cartilage proteoglycans. 
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Aim: The aim of this study was to compare a synthetic Hyaluro- 
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nan (OstenilP TMP) to a corticosteroid injection (Depomedrone) for 
primary subacromial impingement of the shoulder. 
Methods: In a retrospective review, thirty one patients with pri- 
mary subacromial impingement of the shoulder were randomly 
given either a 40mg Depomedrone injection or Ostenil injection. 
No patients had undergone previous surgery. All had physiother- 
apy following the injection. Patients were given a Pain Diary with 
a ten point visual analogue scale to complete. 
Results: There was no difference between the two groups with 
regard to age and sex. 
Both steroid and Ostenil reduce the pain score in the first two 
to four hours post-injection, but in the Depomedrone group the 
pain score increases significantly from 12 hours to 2 days post- 
injection. This effect is not observed with Ostenil. This differ- 
ence is significant (p<0.05) between 18 hours and 3 days post- 
injection. From 4 days the pain score is similar, with an equal 
reduction in pain in the two groups. 
Conclusions: Ostenil Hyaluronan appears to be as effective as 
Depomedrone in reducing subacromial impingement pain, but 
does not produce the pain surge associated with Depomedrone 
in the first few days post-injection. 
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Background: The WOMAC questionnaire has three sections: 
pain, stiffness, and function. The original function section (sec- 
tion C) has 17 items but shortened versions with eight and nine 
items have recently been proposed. 
Aims: To assess and compare construct validity of the 17, nine, 
and 8eight-item versions of the WOMAC questionnaire. 
Methods: In a cross sectional national survey, 1811 GPs enrolled 
5324 patients with hip and/or knee osteoarthritis (OA). Pain at 
rest and during activities, and mean pain for the previous eight 
days were recorded on a 11-point numeric scale, and function 
was assessed using the 17, nine, and eight item-versions of the 
WOMAC, section C. Construct validity was assessed using the 
Chronbach coefficient, and factor analysis followed by orthogo- 
nal rotation. Coefficient correlations between mean scores were 
determined with Spearman's rank correlation coefficient. 
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Results: 4719 patients (88.6%) were analysed (2781 with 
knee, 1553 with hip, and 385 with hip and knee osteoarthritis). 
Mean scores of the WOMAC (range 0-100) were 48.74-17.9, 
47.24-17.4, and 52.24-17.5 for the 17, nine, and eight item- 
versions respectively. We observed no difference in mean scores 
between knee and hip osteoarthritis. For the three versions of the 
questionnaire, the Cronbach coefficient values were high (0.96, 
0.91, and 0.92 respectively). For each osteoarthritis location, fac- 
tor analysis of the 17-item version extracted two similar factors 
which could not be clinically characterised, explaining 67% of the 
total variance for hip OA and 63% of the total variance for knee 
OA. Factor analysis of the nine-item version extracted one fac- 
tor explaining 60% of the total variance for knee and two fac- 
tors (which could not be clinically characterised) explaining 72% 
of the total variance for hip osteoarthritis. The eight-item version 
was one-dimensional for knee and hip OA, explaining 61.0% and 
61.5% of total variance. The mean scores of the three WOMAC 
versions were highly correlated but were weakly correlated with 
pain scores (r values between 0.42 and 0.53). 
Conclusions: Mean scores of the 3 versions of the WOMAC 
questionnaire, section C are highly correlated, but the eight-item 
version has the advantage of being one-dimensional for both lo- 
cations of the disease. Disability assessed by the WOMAC ques- 
tionnaire is similar for both hip and knee osteoarthritis. 
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Introduction: There are many treatment pathways for os- 
teoarthritis of the knee; however the outcome may not match the 
patient's expectations. The purpose of this study was to identify 
the expectations of treatment in patients with osteoarthritis of the 
knee. 
Methods: A 20 item validated knee surgery expectation survey 
was completed by 130 individuals, 50 years or older, who were 
diagnosed with knee osteoarthritis. There were 54 women and 
76 men with a mean age of 63 years(range 50 - 91). 
Results: Avoid future knee degeneration was the most com- 
mon expectation rated very important(85%), followed by improve 
ability to maintain health(79%), have confidence in knee(69%), 
and improve ability to walk(69%). The least common expecta- 
tion was for the knee to be back to way it was before the prob- 
lem started, followed by improve ability to run. Gender was as- 
sociated (p<0.05) with the following expectations: avoid future 
degeneration(more important o females), improve ability to do 
stairs(more important o females), improve ability to kneel(more 
important o males), and stop knee from giving way when stop- 
ping quickly(more important to males). Age was associated 
(p<0.05) with pain relief(more important to younger) and improve 
ability to participate in sport(more important to younger). Improve 
ability to maintain health was more important to older individuals, 
as was avoid future degeneration of the knee. 
Conclusions: Patient expectations are influenced by age and 
gender. These differences are important in clinical decision mak- 
ing. Further understanding of patients' expectations of treatment 
may improve treatment outcome and patient satisfaction. 
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Aim of study: After observing that three patients with both knee 
osteoarthritis and psoriasis treated with chondroitin sulfate ex- 
perienced a marked improvement of skin lesions, we decided to 
study more cases due to the encouraging preliminary results. 
Here, we describe the clinical and histopathological results of 
eleven patients with both osteoarthritis and psoriasis treated with 
oral chondroitin sulfate. 
Methods: Eleven adult patients with knee osteoarthritis and long- 
standing moderate to severe psoriasis resistant to conventional 
therapy received 800 mg/day of chondroitin sulfate (Bioiberica 
S.A., Barcelona, Spain) for two months. Skin biopsies were ob- 
tained before and after treatment. 
Results: Clinically, all patients but one presented a dramatic im- 
provement of the condition of the skin with a reduction of swelling, 
redness, flaking, and itching, increase in the hydration and soft- 
ening of the skin, and amelioration of scaling. One patient expe- 
rienced clearance of psoriasis. Histopathologically, there was a 
statistically significant decrease in epidermal thickness (-29%), 
a decrease in the thickness between the stratum basale and 
the stratum granulosum (-31%), a significant improvement of the 
degree of psoriasis activity (-49%), and a decrease in the ker- 
atinocyte proliferation index (-27%). The substitution of paraker- 
atotic keratinization by orthokeratotic keratinization was also ob- 
served. 
Conclusions: The administration of chondroitin sulfate resulted 
in a marked improvement of the psoriatic lesions. Therefore, the 
confirmation of these findings in controlled prospective studies 
could represent an important advance in the therapeutic arma- 
mentarium for patients with psoriasis given the excellent safety 
profile of chondroitin sulfate. 
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Aims: To compare the effectiveness of Ostenil Mini (a Sodium 
Hyaluronate designed specifically for small joint Osteoarthritis) to 
a standard injection of Depomedrone for base of thumb arthritis. 
Methods: After obtaining ethical approval 20 patients were re- 
cruited from the Rheumatology and Hand clinics at a busy dis- 
trict general hospital and gave consent to be included in the trial. 
Patients received either an injection of Depomedrone or an in- 
jection of Ostenil mini. Due to bilateral disease there were 23 
injections, 10 of Depomedrone and 13 of Ostenil mini. Most pa- 
tients were female; 2 males, and only 2 were left-handed, both 
of these had isolated left sided disease. Each patient was as- 
sessed prior to the injection using the Patient Rated Wrist Evalua- 
